Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mil Med Res ; 7(1): 4, 2020 02 06.
Artículo en Inglés | MEDLINE | ID: mdl-32029004

RESUMEN

In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named "2019 novel coronavirus (2019-nCoV)" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus , Infección Hospitalaria , Control de Infecciones , Tamizaje Masivo , Equipo de Protección Personal , Neumonía Viral , Antibacterianos/uso terapéutico , Antivirales/uso terapéutico , Betacoronavirus/aislamiento & purificación , Betacoronavirus/patogenicidad , COVID-19 , Prueba de COVID-19 , Técnicas de Laboratorio Clínico , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/transmisión , Infección Hospitalaria/prevención & control , Diagnóstico Diferencial , Medicamentos Herbarios Chinos , Medicina Basada en la Evidencia , Fluidoterapia , Humanos , Control de Infecciones/normas , Pulmón/diagnóstico por imagen , Epidemiología Molecular , Atención de Enfermería , Neumonía Viral/diagnóstico , Neumonía Viral/epidemiología , Neumonía Viral/etiología , Neumonía Viral/terapia , Neumonía Viral/transmisión , SARS-CoV-2 , Tratamiento Farmacológico de COVID-19
2.
Curr Med Sci ; 38(4): 697-703, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30128881

RESUMEN

This study examined the effect of saponins from Tupistra chinensis Bak (STCB) on the growth of sarcoma S-180 cells in vitro and in mouse xenografts as well as the underlying mechanisms. Cell proliferation was assessed by MTT assay. Cell cycle distribution was determined by flow cytometry. Sarcoma S-180 tumor-bearing mice were treated with different doses of STCB with 10 µg/mL 5-fluorouracil (5-Fu) as a positive control. The activity of nuclear factor (NF)-κB was detected by gel mobility shift assay. The mRNA level of NF-κB was determined by real-time quantitative RT-PCR. The results showed that in vitro STCB inhibited the growth of S-180 cells in a concentration-dependent manner, which was accompanied by cell cycle arrest at S-phase. In vivo STCB significantly inhibited the growth of S-180 tumor mouse xenografts in a dose-dependent manner with apparent induction of cell apoptosis. Moreover, STCB inhibited the activity of NF-κB p65 and reduced the expression of NF-κB p65 mRNA in mouse xenografts. It was concluded that STCB inhibits the proliferation and cell cycle progression of S-180 cells by suppressing NF-κB signaling in mouse xenografts. Our findings suggest STCB is a promising agent for the treatment of sarcoma.


Asunto(s)
Antineoplásicos/uso terapéutico , Saponinas/uso terapéutico , Sarcoma Experimental/tratamiento farmacológico , Factor de Transcripción ReIA/metabolismo , Animales , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Asparagaceae/química , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Saponinas/farmacología , Sarcoma Experimental/metabolismo , Transducción de Señal , Factor de Transcripción ReIA/genética
3.
Exp Ther Med ; 11(6): 2477-2483, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27284335

RESUMEN

Danggui Buxue Tang (DBT) is a simple combination of Radix Astragali and Radix Angelica sinensis (5:1), with a variety pharmacological activities. In the present study, a single intravenous injection of 30 mg/kg streptozotocin and subsequent six weeks of high glucose diet in Sprague Dawley rats were used to induce diabetic nephropathy. Rats with diabetes mellitus showed increased levels of fasting blood glucose (FBG), blood urea nitrogen (BUN), serum creatinine (Scr), serum and urine ß2-microglobulins (ß2-MG), and type IV collagen (all P<0.05). DBT treatment significantly decreased the levels of FBG, BUN, Scr, serum and urine ß2-MG, and type IV collagen. Furthermore, DBT treatment significantly and dose-dependently restored the ultrastructural injury, and reduced the expression of heparanase, compared with the vehicle (P<0.05). Therefore, DBT may be a novel therapeutic approach for the prevention and treatment of diabetic nephrology.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...